Achilles Therapeutics to Present at Upcoming Investor Conferences
02 September 2021 - 10:30PM
Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage
biopharmaceutical company developing precision T cell therapies to
treat solid tumors, today announced that management will present at
the following investor conferences in September.
- Wells Fargo Virtual
Healthcare Conference on Friday, September 10, 2021 at
10:40am ET / 3:40pm UK
- H.C. Wainwright 23rd Annual
Global Investment Conference available beginning Monday,
September 13, 2021 at 7:00am ET / 12:00pm UK
- Oppenheimer Fall Healthcare
Life Sciences & MedTech Summit on Wednesday, September
22, 2021 at 8:15am ET / 1:15pm UK
A live and archived webcast of the presentations
will be available in the Events & Presentations section of
the Achilles website.
About Achilles
TherapeuticsAchilles is a clinical-stage biopharmaceutical
company developing precision T cell therapies targeting clonal
neoantigens: protein markers unique to the individual that are
expressed on the surface of every cancer cell. The Company has two
ongoing Phase I/IIa trials, the CHIRON trial in patients with
advanced non-small cell lung cancer (NSCLC) and the THETIS trial in
patients with recurrent or metastatic melanoma. Achilles uses DNA
sequencing data from each patient, together with its proprietary
PELEUS™ bioinformatics platform, to identify clonal neoantigens
specific to that patient, and then develop precision T cell-based
product candidates specifically targeting those clonal
neoantigens.
Further information:
Lee M. Stern – VP, IR & External
Communications+1 (332) 373-2634l.stern@achillestx.com
Consilium Strategic CommunicationsMary-Jane
Elliott, Sukaina Virji, Melissa Gardiner+44 (0) 203 709
5000achillestx@consilium-comms.com
Achilles Therapeutics (NASDAQ:ACHL)
Historical Stock Chart
From Sep 2024 to Oct 2024
Achilles Therapeutics (NASDAQ:ACHL)
Historical Stock Chart
From Oct 2023 to Oct 2024